Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1998
Business Overview: Bio-Rad operates in three primary segments: Clinical Diagnostics, Life Science, and Analytical Instruments. The company is a Delaware corporation headquartered in Hercules, California.
Key Financial Metrics
| Metric (in thousands) | Q3 1998 | Q3 1997 | 9 Months 1998 | 9 Months 1997 |
|---|---|---|---|---|
| Net Sales | $98,982 | $99,491 | $323,054 | $311,097 |
| Gross Profit | $53,577 | $54,835 | $176,510 | $175,697 |
| Gross Margin % | 54.1% | 55.1% | 54.6% | 56.5% |
| Income from Operations | $2,292 | $3,909 | $22,116 | $21,491 |
| Net Income | $1,938 | $2,614 | $17,865 | $15,007 |
| Diluted EPS | $0.16 | $0.21 | $1.44 | $1.21 |
| Cash & Equivalents (End of Period) | $8,335 | $10,843 | $8,335 | $4,672 |
| Total Debt (Current + Long-term) | $48,732 | $49,754 | $48,732 | $49,754 |
Note: Debt figures derived from "Notes payable and current maturities" ($10,001) and "Long-term debt" ($38,731) as of Sept 30, 1998.
Material Changes vs. Prior Period
- Revenue: Q3 1998 sales were flat compared to Q3 1997 ($99.0M vs $99.5M). However, on a currency-neutral basis, sales increased 12% in Clinical Diagnostics and 5% in Life Science, while Analytical Instruments dropped 24%. The strengthening U.S. dollar reduced international sales by approximately $3.1 million in Q3.
- Profitability: Operating income declined 41% in Q3 ($2.3M vs $3.9M) due to lower gross margins and higher SG&A expenses. Gross margins compressed to 54.1% from 55.1% due to currency effects and the impact of the Chiron Diagnostics acquisition.
- Expenses: SG&A increased to 41.5% of sales in Q3 (up from 40.2% in 1997). R&D expenses decreased in absolute dollars and as a percentage of sales.
- Investment Activity: The company realized significant investment income ($2.0M in Q3, $6.8M YTD) from selling marketable securities to fund a 25% stake in Instrumentation Laboratory, S.p.A. (IL).
- Debt: The company entered a new $100 million revolving credit agreement in May 1998, replacing a $60 million facility. Borrowings increased temporarily to fund the IL investment but returned to prior levels by quarter-end.
Guidance, Outlook, and Risks
- Outlook: Management expects SG&A growth to moderate in 1998 relative to sales. They anticipate the effective tax rate will rise as loss carryforwards are exhausted.
- Market Conditions: The Analytical Instruments segment faces a general market slowdown, particularly in semiconductor test equipment, with delayed system orders. Economic conditions in Asia continue to negatively impact all segments.
- Year 2000 (Y2K) Risk: Estimated remediation costs are $8 million, with half incurred to date. The company faces significant risk regarding the Y2K readiness of suppliers and global infrastructure (banking, power, transport), which could materially disrupt operations.
- Euro Transition: The company is preparing for the Euro introduction in 1999, expecting increased competitive pressures and the need for system adjustments, though no material financial impact is currently anticipated.
- Inventory: Inventories increased $5.5 million YTD, primarily in Life Science, to meet expected Q4 demand and new product launches. Management is monitoring obsolescence risks.
Investor Verification Checklist
- Segment Performance: Verify the sustainability of the 24% decline in Analytical Instruments sales and the impact of the semiconductor market slowdown.
- Investment in IL: Confirm the valuation and liquidity status of the 25% stake in Instrumentation Laboratory, S.p.A., which was reclassified from Marketable Securities to Other Assets due to lack of a liquid market.
- Y2K Contingency: Assess the progress of supplier remediation responses and the adequacy of the $8 million budget for IT system upgrades.
- Margin Pressure: Monitor whether gross margins can recover from the impact of the Chiron acquisition and currency fluctuations.
- Debt Utilization: Track the utilization of the new $100 million credit facility and the company's ability to service debt given the recent increase in interest expense.